ライフサイエンスコーパス: LPA

1 LPA also diminished the adhesive capacity of EOC single

2 LPA also induced expression of interleukin-1beta (IL-1be

3 LPA defined four profiles of men based on these biomarke

4 LPA disrupts junctional integrity and epithelial cohesio

5 LPA enhanced TNF-alpha mRNA through NF-kappaB-mediated t

6 LPA exposure leads to the loss of N-cadherin concentrati

7 LPA is a promising tool to predict correctly different d

8 LPA is produced extracellularly by autotaxin (ATX), a se

9 LPA profiling may help researchers to identify the most

10 LPA promotes binding of Rel family transcription factors

11 LPA signaling induced NFAT1 nuclear translocation, sugge

12 LPA species with longer chain polyunsaturated acyl group

13 LPA stimulates pathways regulated by small GTPases throu

14 LPA treatment in mice enhanced liver mitochondrial activ

15 LPA using routinely collected clinical data could identi

16 LPA was first identified as a vasoactive compound becaus

17 LPA(1) is one of six known receptors (LPA(1-6)) for lyso

18 LPA-LPAR signaling has been implicated in development of

19 LPA-mediated mitochondrial homeostasis is regulated by C

20 LPA-stimulated Akt/mTOR signaling is critical for LPA-me

21 LPA/LPAR1 regulates ciliogenesis initiation via downstre

22 defined G protein-coupled receptors (LPA(1)-LPA(6)).

23 Lyso-phosphatidic acid-18:2 (LPA-18:2) was the only lipid with significantly lower ab

24 the present study, mRNA expression of all 6 LPA receptor genes was detected in murine aortic VSMCs,

25 with measurements of plasma lipoprotein(a), LPA kringle-IV type 2 number of repeats, and LPA rs10455

26 bated mouse plasma, which contained abundant LPA, also induced a hypertensive response.

27 High-gradient laser-plasma accelerators (LPA) have been proposed as a possible platform, but no e

28 Laser-plasma accelerators (LPAs) are capable of accelerating charged particles to v

29 Laser Plasma Accelerators (LPAs), delivering GeV electron beams in few centimeters,

30 le in the production of lysophosphatic acid (LPA) species in blood.

31 ivation of the type 1 lysophosphatidic acid (LPA(1)) receptor is a crucial factor in the initiation o

32 c acid synthesis from lysophosphatidic acid (LPA) and acyl-coenzyme A.

33 LPC) to the bioactive lysophosphatidic acid (LPA) and choline.

34 s the bioactive lipid lysophosphatidic acid (LPA) and is a drug target of considerable interest for n

35 aluated the effect of lysophosphatidic acid (LPA) and its analog, Radioprotein-1, on gamma-radiation-

36 actions of bioactive lysophosphatidic acid (LPA) and sphingosine 1 phosphate, which likely explains

37 two bioactive lipids, lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P).

38 Lysophosphatidic acid (LPA) functions through activation of LPA receptors (LPAR

39 Lysophosphatidic acid (LPA) has been recognized recently as an endothelium-depe

40 Elevated levels of lysophosphatidic acid (LPA) have been linked to aberrant cell proliferation, on

41 of the lipid mediator lysophosphatidic acid (LPA) in biological fluids.

42 in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl cho

43 or the lipid mediator lysophosphatidic acid (LPA) in decidualization, acting through its G-protein-co

44 ptor 1 (LPAR1), serum lysophosphatidic acid (LPA) inhibits Rab11a-Rabin8 interaction and ciliogenesis

45 Lysophosphatidic acid (LPA) is a blood-derived bioactive lipid with numerous bi

46 Lysophosphatidic acid (LPA) is a phospholipid that acts as an extracellular sig

47 Lysophosphatidic acid (LPA) is an endogenous cell signaling molecule, and dysre

48 Lysophosphatidic acid (LPA) is an important mediator of pulmonary fibrosis.

49 small bioactive lipid lysophosphatidic acid (LPA) plays critical roles in both normal physiology and

50 ble for extracellular lysophosphatidic acid (LPA) production, and was among the top ten upregulated g

51 ment of fibrosis, and lysophosphatidic acid (LPA) promotes fibrosis by regulating multiple fibroblast

52 ously, we showed that lysophosphatidic acid (LPA) receptor 1 regulates proliferation of intestinal ep

53 t the bioactive lipid lysophosphatidic acid (LPA) regulates hepatocyte glucose production by antagoni

54 The lipid mediator lysophosphatidic acid (LPA) signals via six distinct G protein-coupled receptor

55 Lysophosphatidic acid (LPA) stimulates the formation of stabilized detyrosinate

56 iated (GPAT-mediated) lysophosphatidic acid (LPA) synthesis.

57 tidylcholine (LPC) or lysophosphatidic acid (LPA) to cells restored their oxidant generation.

58 Lysophosphatidic acid (LPA), a growth factor-like phospholipid, regulates numer

59 Lysophosphatidic acid (LPA), a lipid by-product of autotaxin activity, is invol

60 we demonstrated that lysophosphatidic acid (LPA), a lipid mediator present in ascites of ovarian can

61 zes the production of lysophosphatidic acid (LPA), a pleiotropic growth-factor-like lysophospholipid.

62 ipase D that produces lysophosphatidic acid (LPA), a pleiotropic lipid mediator acting on specific GP

63 y signal initiated by lysophosphatidic acid (LPA), an upstream regulator of Yap that can cause fetal

64 T1), autotaxin (ATX), lysophosphatidic acid (LPA), and beta-catenin that contributes to progression o

65 ts enzymatic product, lysophosphatidic acid (LPA), are elevated during HCV infection, and LPA activat

66 a the signaling lipid lysophosphatidic acid (LPA), linking it with GPAM to cell migration.

67 t the bioactive lipid lysophosphatidic acid (LPA), prevalent in the EOC microenvironment, functions t

68 GF23 via increases in lysophosphatidic acid (LPA), which activates the LPA receptor 1 in FGF23-secret

69 al sensitivity toward lysophosphatidic acid (LPA), which failed to repel PRG-2-deficient thalamocorti

70 ogenic lipids such as lysophosphatidic acid (LPA).

71 nse to treatment with lysophosphatidic acid (LPA).

72 es the lipid mediator lysophosphatidic acid (LPA).

73 eptors (LPA(1-6)) for lysophosphatidic acid (LPA).

74 tor agonists, notably lysophosphatidic acid (LPA; acting through the LPA1 receptor) and endothelin.

75 oline (LPC 18:1) and lysophosphatidic acids (LPAs) in the intestine and plasma.

76 ality attributable to low physical activity (LPA) in China and Japan during the period 1990-2016.

77 a (INV), lepidic-predominant adenocarcinoma (LPA), and adenocarcinoma in situ (AIS)/minimally invasiv

78 Infection using large-particle aerosol (LPA) delivery was further confirmed in nonhuman primates

79 ontrast, TNF-alpha inhibition did not affect LPA-dependent cell proliferation.

80 INF2 localized to MTs after LPA treatment in an mDia1-dependent manner, suggesting t

81 formation of leukocyte-platelet aggregates (LPA) that facilitated leukocyte infiltration to the affe

82 regulation of focal adhesion signaling in an LPA-dependent manner.

83 The functional consequence is an LPA-induced dissemination of small mesenchymal-type clus

84 mic signatures of LPA and S1P, suggesting an LPA/S1P-mediated reprogramming of the TSC lipidome.

85 he generation of undulator radiation with an LPA beam based manipulation in a dedicated transport lin

86 Here, we used latent profile analysis (LPA) to assess whether these biomarkers cluster within t

87 se were analyzed by latent profile analysis (LPA) to identify whether subphenotypes existed.

88 The latent profile analysis (LPA), with data of seven in vitro methods and one assay

89 1/14:0, mono-hexosylceramide-d18:1/20:0, and LPA-18:2 may represent important targets for future stud

90 ATX and LPA have been implicated in key (patho)physiologic proce

91 M, K(D) = 19.6 nM; inactive at autotaxin and LPA(2-6) receptors).

92 rs identify associations at HLA-DQA/DRB1 and LPA and find that genetic variants that increase educati

93 associated with longevity (HLA-DQA1/DRB1 and LPA).

94 ood correlation between the hypertensive and LPA(4) agonistic activities.

95 LPA), are elevated during HCV infection, and LPA activates immunocytes, but whether this contributes

96 bstrate-product relationship between LPC and LPA in pulmonary fibrosis.

97 rebral, peripheral), including LDLR, LPL and LPA, suggesting that therapeutic modulation of low-densi

98 elated with IL-6, sCD14, sCD163, Mac2BP, and LPA levels in HCV-infected participants and with Mac2BP

99 The low-perfusion map and LPA and FPL parameters are able to assess the location a

100 and the crosstalk between TP53 mutations and LPA signaling, we utilized primary fallopian tube epithe

101 Further, the stimulatory effect of G-3-P and LPA on FGF23 required LPA receptor 1 (LPAR1).

102 LPA kringle-IV type 2 number of repeats, and LPA rs10455872.

103 was dependent on autocrine ATX secretion and LPA signaling.

104 taneously harbouring TUDCA in the tunnel and LPA in the pocket, together with kinetic analysis, revea

105 Here, we engineer the Light Plate Apparatus (LPA), a device that can deliver two independent 310 to 1

106 ed with a novel Luminex-based peptide assay (LPA).

107 th strains susceptible by line-probe assays (LPAs) to second-line drugs.

108 receptor, LPA(6), also showed an attenuated LPA-induced hypertensive response.

109 a confirms that our lead compound attenuates LPA mediated signaling in cells and reduces LPA synthesi

110 itive inhibitors of ATX, thereby attenuating LPA receptor activation.

111 ATX-LPA receptor signaling is essential for normal developme

112 ATX-LPA signalling is involved in multiple biological and pa

113 The autotaxin-lysophophatidic acid (ATX-LPA) signaling pathway is implicated in a variety of hum

114 Thus, together, our data suggest that an ATX-LPA-HDAC1/2 axis regulates OLG differentiation specifica

115 This unexpected interplay between ATX-LPA signalling and select steroids, notably natural bile

116 As a result, ATX-LPA has become of significant interest within both the i

117 Our results indicate that ATX-LPA-LPA3 signaling at the embryo-epithelial boundary ind

118 The ATX-LPA pathway has been implicated in many pathologic condi

119 The ATX-LPA signaling axis arouses a high interest in the drug d

120 The ATX-LPA signaling pathway is implicated in cell survival, mi

121 This study identifies activation of the ATX-LPA/S1P pathway as a novel mode of metabolic dysregulati

122 established a liver profibrotic role for ATX/LPA, whereas pharmacological ATX inhibition studies sugg

123 noma (HCC) development, thus implicating ATX/LPA in the causative link of cirrhosis and HCC.

124 FOXF1 promotes LR-MSC migration via the ATX/LPA/LPA1 signaling axis.

125 ear translocation, suggesting that autocrine LPA synthesis promotes NFAT1 transcriptional activation

126 Autotaxin, LPA, and sCD14 levels normalized, while sCD163 and Mac2B

127 A role for the autotaxin/LPA axis has been suggested in many disease areas includ

128 e hemispheric difference correlation between LPA and VF (rho = 0.595).

129 med a phenome-wide association study between LPA genotypes and 19,202 phenotypes to demonstrate that

130 receiver operating curve was 0.965 for both LPA and FPL, with a sensitivity of 93.7% at 95% specific

131 educed acute stimulation of NHE3 activity by LPA/LPA5R stimulation; and 3) reduced acute inhibition o

132 responses to LPA, induction of TNF-alpha by LPA also depended on the transactivation of the epiderma

133 sponsible for the transactivation of EGFR by LPA in ovarian cancer cells.

134 r for models using IgE plus IgG4 epitopes by LPA (84.8%), twice the performance of the serum componen

135 interaction of mDia1 and INF2 was induced by LPA and dependent on IQGAP1.

136 bility of a tripartite complex stimulated by LPA.

137 The di-C18 LPAs share the ability of burying their lipid chains in

138 e demonstrate for the first time that di-C18 LPAs trigger pro-inflammatory responses through Toll-lik

139 ch led to the identification of 86 candidate LPA-binding proteins in HEK293T cells.

140 This compound induces characteristic LPA(1)-mediated cellular effects and prompts the interna

141 her, these results indicate that circulating LPA produced by ATX contributes to the elevation of bloo

142 the synthesis of a desthiobiotin-conjugated LPA acyl phosphate probe for the covalent labeling, enri

143 shown through its ability to rapidly control LPA-evoked increases in intracellular Ca(2+) levels.

144 GTPases through binding to G-protein-coupled LPA receptors (LPARs).

145 KO mice of another Galpha(12/13)-coupling LPA receptor, LPA(6), also showed an attenuated LPA-indu

146 KO mice of LPA(4), a Galpha(12/13)-coupling LPA receptor.

147 al LPA analogs with varied affinity for each LPA receptor, we found a good correlation between the hy

148 tration in plasma 0.95, 0.81-1.11 and either LPA SNP 1.10, 0.92-1.31) or cardiovascular mortality (0.

149 ial infarction per 1-SD difference in either LPA KIV2 repeats or lipoprotein(a) concentration.

150 95% CI 1.14-1.83) and the presence of either LPA SNP (1.88, 1.40-2.53).

151 (PLPP1) had a 2-fold increase in endogenous LPA levels, reduced PEPCK levels during fasting, and dec

152 dvanced irradiation schemes with an existing LPA source.

153 olumes can already be obtained with existing LPA technology, calling for dedicated pre-clinical studi

154 atment of primary hepatocytes with exogenous LPA blunted glucagon-induced PEPCK expression and glucos

155 Stable electron beams from a first LPA were focused to a twenty-micrometre radius--by a dis

156 er than the 14.5% (95% CI: 10.3%, 18.7%) for LPA (P = .002).

157 aclass correlation coefficient was 0.977 for LPA and 0.958 for FPL.

158 otein(a) concentration, after adjustment for LPA KIV2 repeats and conventional lipids.

159 timulated Akt/mTOR signaling is critical for LPA-mediated macrophage development in mice.

160 lternative enzymatic pathways also exist for LPA production.

161 These findings identify a critical role for LPA in regulating innate immune system.

162 1 antagonist, confirming an in vivo role for LPA signaling in beta-catenin activation.

163 out mice, we previously uncovered a role for LPA signaling in promoting colitis and colorectal cancer

164 e been instrumental in identifying roles for LPA-LPA(1) signaling in neurobiological processes, brain

165 had a trend toward being lower than that for LPA (P = .051).

166 ty rates (ASMRs) showed declining trends for LPA-attributable stroke mortality.

167 probe morphological changes that result from LPA treatment.

168 r by increased frequency of the rs10455872-G LPA risk allele (15.1% vs. 8.8%; p < 0.05).

169 el risk locus was identified within the gene LPA (rs12207195; posterior probability 0.925) after rewe

170 low-frequency missense variants in the genes LPA and PCSK9.

171 To date, only 2 genes, LPA and PALMD, have been identified as causal for CAVS.

172 Similarly, orally given LPA blocked tumor necrosis factor-mediated intestinal ba

173 novel role for PLPP1 activity and hepatocyte LPA levels in glucagon sensitivity via a mechanism invol

174 However, LPA(6) KO mice also displayed attenuated pressor respons

175 In humans, LPA mediates macrophage formation following similar path

176 Importantly, LPA did not blunt glucagon-stimulated glucose production

177 I 0.90-0.97; p<0.0001) per 1-SD increment in LPA KIV2 repeats after adjustment for lipoprotein(a) con

178 an involvement of oncogenic p53 mutations in LPA signaling and HGSOC progression through regulation o

179 ermine apo(a) size), and a splice variant in LPA associated with small apo(a) but low Lp(a) molar con

180 atocyte ATX expression, leading to increased LPA levels, activation of hepatic stellate cells (HSCs),

181 at are attenuated by an NF-kappaB inhibitor, LPA receptor antagonists, and inhibitors of phosphoinosi

182 dings show how GPAM influences intracellular LPA levels to promote cell migration and tumor growth.

183 radixin accumulation in growth cones and its LPA-dependent phosphorylation depend on its binding to s

184 Autotaxin (ATX) is a key LPA-producing enzyme, and we hypothesized that ATX contr

185 r results establish that the bioactive lipid LPA drives the expression of TNF-alpha to regulate an in

186 Lipopolyamines (LPAs) are cationic lipids; they interact spontaneously w

187 cade, kNN-TTP, Lesion-TOADS, LST-LGA and LST-LPA).

188 cross scanners, for kNN-TTP, followed by LST-LPA and LST-LGA, with worse performance for Lesion-TOADS

189 ssure through multiple LPA receptors, mainly LPA(4).

190 Mechanistically, LPA antagonized glucagon-mediated inhibition of STAT3, a

191 In Caco-2 and m-IC(C12) cell monolayers, LPA attenuated radiation-induced redistribution of TJ pr

192 elevation of blood pressure through multiple LPA receptors, mainly LPA(4).

193 Together, we developed a novel LPA probe for the identification and characterizations o

194 The pharmacological activation of LPA receptor subtypes represent a novel strategies for a

195 c acid (LPA) functions through activation of LPA receptors (LPARs).

196 AzoLPA shows greater activation of LPA receptors in its light-induced cis-form than its dar

197 , we report on a photoswitchable analogue of LPA, termed AzoLPA, which contains an azobenzene photosw

198 ion of LPC for conversion to LPA; binding of LPA to LPAR1 signals rac activation.

199 the identification and characterizations of LPA-binding proteins from the entire human proteome.

200 us effect is suggested by the consumption of LPA that augments mitochondrial metabolic homeostasis vi

201 AzoLPA enables optical control of LPA receptor activation, shown through its ability to ra

202 The longitudinal age curves of LPA-attributable stroke mortality were higher in men tha

203 nscriptional regulator in the development of LPA-induced macrophages.

204 ell signaling molecule, and dysregulation of LPA signaling pathways is accompanied by several types o

205 al angiomyolipomas have higher expression of LPA receptor 1 and S1P receptor 3 compared with normal k

206 view the developmentally related features of LPA signalling.

207 Here, we reveal an unexpected function of LPA that transfigures CD11b(+) murine monocytes into F4/

208 proach to further elucidate the functions of LPA receptors during red blood cell (RBC) differentiatio

209 e likely responsible for local generation of LPA in the injured lung.

210 t, and subsequent LC-MS/MS identification of LPA-binding proteins at the proteome-wide level.

211 thod for the proteome-wide identification of LPA-binding proteins.

212 Decreased levels of LPA-18:2 were detected in patients with more rapid disea

213 his, the response was weakened in KO mice of LPA(4), a Galpha(12/13)-coupling LPA receptor.

214 To explore the biological outcomes of LPA-induced TNF-alpha, we examined the effects of a TNF-

215 1 was able to cause a sustained reduction of LPA levels in plasma in vivo and was shown to be efficac

216 However, the role of LPA-LPAR signaling in development of diabetic nephropath

217 Here we describe a new series of LPA(1) agonists among which derivative (S)-17 (UCM-05194

218 tudies revealed transcriptomic signatures of LPA and S1P, suggesting an LPA/S1P-mediated reprogrammin

219 In addition, supplementation of LPA or S1P rescued proliferation and viability, neutral

220 rease in lipid composition on the surface of LPA-treated cells.

221 onal mouse mutant expand an understanding of LPA(1) signaling in the PSNL model of neuropathic pain.

222 and abdominal aorta (AA) segments, 1-oleoyl-LPA and the LPA1-3 agonist VPC31143 induced dose-depende

223 nd recombinant TNF-alpha soluble receptor on LPA-stimulated expression of pro-tumorigenic cytokines a

224 Whether lipoprotein(a) concentrations or LPA genetic variants predict long-term mortality in pati

225 otoxic effects in liver cells, low-level PA (LPA) increases mitochondrial functions and alleviates th

226 Eight loci (PCSK9, LPA, LPL, LIPG, ANGPTL4, APOB, APOC3, and CD300LG) remai

227 ound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.

228 an that of commercial linear polyacrylamide (LPA)-coated capillaries.

229 Proof-of-principle LPA based undulator emission, with strong electron focus

230 and multiple tumor types, autotaxin produces LPA from lysophosphatidylcholine (LPC) via lysophospholi

231 ned the role of autotaxin (ATX) in pulmonary LPA production during fibrogenesis in a bleomycin mouse

232 and in the lung, without effect on pulmonary LPA or fibrosis.

233 another Galpha(12/13)-coupling LPA receptor, LPA(6), also showed an attenuated LPA-induced hypertensi

234 e family of lysophosphatidic acid receptors (LPA(1-6)).

235 ugh six defined G protein-coupled receptors (LPA(1)-LPA(6)).

236 LPA(1) is one of six known receptors (LPA(1-6)) for lysophosphatidic acid (LPA).

237 LPA mediated signaling in cells and reduces LPA synthesis in vivo, providing a promising natural pro

238 x deposition in the lung while also reducing LPA 18:2 content in bronchoalveolar lavage fluid.

239 ry effect of G-3-P and LPA on FGF23 required LPA receptor 1 (LPAR1).

240 ur findings strengthen the argument for safe LPA-targeted intervention to reduce cardiovascular risk.

241 demonstrates that potentially any saturated LPA currently used or proposed as transfection agent is

242 lary-based active plasma lens--into a second LPA, such that the beams interacted with the wakefield e

243 stands out as the most potent and selective LPA(1) receptor agonist described so far (E(max) = 118%,

244 Using several LPA analogs with varied affinity for each LPA receptor,

245 Our retrospective study shows LPAs have suboptimal specificity in predicting eligibili

246 EOC MCAs displayed significant LPA-induced changes in surface ultrastructure with the l

247 However, the energy gain in a single-stage LPA can be limited by laser diffraction, dephasing, elec

248 est a mechanism by which the LPP3 substrate, LPA, can regulate PLPP3 expression.

249 ire identification to therapeutically target LPA production in pulmonary fibrosis.

250 a previous study, we have demonstrated that LPA activates erythropoiesis by activating the LPA 3 rec

251 Our findings indicate that LPA causes vasoconstriction in VSMCs, mediated by LPA1-,

252 protein in response to LPA, indicating that LPA-mediated TNF-alpha production relies on both transcr

253 Using FRET-based biosensors, we show that LPA and endothelin transiently activate Cdc42 through Gi

254 The LPA dramatically reduces the entry barrier to optogeneti

255 The LPA identified three distinct subphenotypes: Profile 1 (

256 The LPA locus link with cardiovascular risk exemplifies how

257 The LPA parameter is the cumulative area, and the FPL is the

258 The LPA was 3.40+/-2.29 mm(2) in those with POAG and 0.11+/-

259 The LPA-induced hypertensive response was significantly atte

260 phosphatidic acid (LPA), which activates the LPA receptor 1 in FGF23-secreting cells in the bone and

261 A activates erythropoiesis by activating the LPA 3 receptor subtype (LPA3) under erythropoietin (EPO)

262 that this new-found interaction between the LPA/LPA1 and TXA2/TP pathways plays significant roles in

263 ulture)-based workflow, we characterized the LPA-binding capabilities of these proteins at the entire

264 nction (GOF) p53 mutations downregulated the LPA-degrading enzyme lysophosphatidic acid phosphatase t

265 n of a distinct 4-aa motif necessary for the LPA-specific acyltransferase (LPAAT) activity impaired G

266 However, the LPA and LPC species that increase in BAL of bleomycin-in

267 hod (kringle IV type 2 [KIV2] repeats in the LPA gene) and a serum-based electrophoretic assay in pat

268 Similarly, knockout mice lacking the LPA-degrading enzyme phospholipid phosphate phosphatase

269 hots, limited by secondary components of the LPA accelerator.

270 g transplant model of BOS, antagonism of the LPA receptor (LPA1) or ATX inhibition decreased allograf

271 ite retraction through its activation of the LPA(2) receptor.

272 Knockout of Lpar3 or inhibition of the LPA-producing enzyme autotaxin (ATX) in pregnant mice le

273 relative to normal mean) integrated over the LPA.

274 Here, we demonstrate that through the LPA receptor 1 (LPAR1), serum lysophosphatidic acid (LPA

275 mined the molecular mechanism underlying the LPA-induced hypertensive response.

276 We use the LPA to precisely control gene expression from blue, gree

277 dels can have appreciable value in using the LPA delivery system to study pulmonary Q fever pathogene

278 pment of renal interstitial fibrosis through LPA-mediated effects on fibroblast functions.

279 Using a novel high-throughput LPA, we were able to distinguish the diversity of IgE/Ig

280 through generation of LPC for conversion to LPA; binding of LPA to LPAR1 signals rac activation.

281 on by generation of LPC that is converted to LPA by the lysophospholipase D activity of autotaxin (AT

282 ating mice and guinea pigs with WCV prior to LPA challenge is capable of eliciting protective immunit

283 of the inflammatory mediators in response to LPA in ovarian cancer cells.

284 l cell indicating a differential response to LPA treatment with cancer progression.

285 m releasing TNF-alpha protein in response to LPA, indicating that LPA-mediated TNF-alpha production r

286 Like many other biological responses to LPA, induction of TNF-alpha by LPA also depended on the

287 d the response of host peritoneal tissues to LPA remain unclear.

288 Two LPA stages were coupled over a short distance (as is nee

289 poprotein(a) concentration in plasma and two LPA single-nucleotide polymorphisms ([SNPs] rs10455872 a

290 In total, 28 patients underwent LPA reanastomosis and/or tracheoplasty in our center, an

291 TLR1 and TLR6-driven heterodimerization upon LPA binding underlines the highly collaborative and prom

292 Using LPA receptor knockout mice, we previously uncovered a ro

293 In vitro, LPA activated monocytes.

294 ility, which was blocked by cotreatment with LPA, but not LPA1 knockdown cells.

295 hoglycerate kinase 1, can bind directly with LPA.

296 neal tissues from healthy mice injected with LPA exhibited enhanced mesothelial surface microvilli.

297 gnals from cellular sheddings from MCAs with LPA treatment are consistent with cleavage of proteins o

298 regates (MCAs) are removed by treatment with LPA.

299 microvilli-like features upon treatment with LPA.

300 cal and chemical responses to treatment with LPA.